Tefibazumab

• CAT Number: I042118
• CAS Number: 521079-87-8
• Purity: ≥95%

Tefibazumab (Cat No.: I042118) is a humanized monoclonal antibody that targets clumping factor A (ClfA), a surface protein of Staphylococcus aureus involved in bacterial adhesion to host tissues. By binding to ClfA, Tefibazumab inhibits bacterial colonization and biofilm formation, enhancing immune clearance and reducing infection severity. It was developed as a potential therapeutic for preventing or treating S. aureus infections, including antibiotic-resistant strains like MRSA. Tefibazumab has been evaluated in clinical trials for its efficacy in reducing infection-related complications in high-risk patients.

Reference

[1]. pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006 Aug;50(8):2751-5.
[Content Brief]

[2]. Reilley S, et, al. Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob Agents Chemother. 2005 Mar;49(3):959-62.
[Content Brief]